Showing results (91-100 of 286) with videos related to

Sort By:
Pageof 29
Acta Endocrinologica|October 1, 1989
Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfismZ Laron, B Klinger, B Erster, et al.
Journal of Endocrinological Investigation|November 5, 2003
Identification of two novel mutations in the human growth hormone receptor geneO Shevah, P Borrelli, M Rubinstein, et al.
Clinical Endocrinology|April 1, 1977
The combined effect of growth hormone and methandrostenolone on the linear growth of patients with multiple pituitary hormone deficienciesA Pertzelan, I Blum, M Grunebaum, et al.
Lancet (London, England)|November 19, 1988
Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfismZ Laron, B Klinger, B Erster, et al.
Regulatory Peptides|October 20, 1993
Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS)R Eshet, B Klinger, A Silbergeld, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 24, 2005
The intellectual capacity of patients with Laron syndrome (LS) differs with various molecular defects of the growth hormone receptor gene. Correlation with CNS abnormalitiesO Shevah, L Kornreich, A Galatzer, et al.
Hormone Research|January 1, 1987
Greater efficiency of human growth hormone therapy in children below five years of age with growth hormone deficiency. A 5-year follow-up studyZ Josefsberg, B Bauman, A Pertzelan, et al.
Lancet (London, England)|May 23, 1992
Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfismZ Laron, S Anin, Y Klipper-Aurbach, et al.
Clinical Endocrinology|August 1, 1991
Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfismZ Laron, B Klinger, L T Jensen, et al.
European Journal of Endocrinology|July 1, 1995
Growth hormone (GH)-releasing heptapeptide, but not GH-releasing hormone, inhibits thyrotropin-stimulated thyroid hormone secretion and cAMP formation in cultured human thyroid folliclesZ Kraiem, C Y Bowers, E Sobel, et al.
Pageof 29